Labetuzumab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | carcinoembryonic antigen |
| Identifiers | |
| CAS Number | 219649-07-7  |
| ATC code | none |
| KEGG | D08936  |
| (what is this?) (verify) |
|
Labetuzumab (marketed under the trade name CEA-CIDE) is a humanized IgG1 monoclonal antibody for the treatment of colorectal cancer.[1] It selectively binds to carcinoembryonic cell adhesion molecule 5. [2]
This drug was developed by Immunomedics, Inc.
References
- ↑ Statement On A Nonproprietary Name Adopted By The Usan Council - Labetuzumab, American Medical Association.
- ↑ http://www.cancer.gov/drugdictionary?cdrid=692828
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Monoclonal antibodies for tumors
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
